IDEXX Laboratories, Inc. IDXX
- Market cap
- $40.2B
- P/E
- 36.2×
Follow IDXX
IDEXX Laboratories, Inc. (IDXX) Free cash flow
IDEXX Laboratories, Inc.'s free cash flow for fiscal 2025 was $1.0B, up 30.8% from $798.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from $138.9M (fiscal 2015) to $1.0B (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. IDEXX Laboratories, Inc. ranks 6th of 52 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.0B | 30.76% |
| FY2024 | $798.1M | 3.26% |
| FY2023 | $772.9M | 101.19% |
| FY2022 | $384.1M | (39.60%) |
| FY2021 | $636.0M | 17.68% |
| FY2020 | $540.4M | 77.81% |
| FY2019 | $303.9M | 9.66% |
| FY2018 | $277.1M | (6.55%) |
| FY2017 | $296.6M | 8.18% |
| FY2016 | $274.2M | 97.40% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $320.6M | 37.92% |
| Mar 2026 | $232.5M | (28.72%) |
| Dec 2025 | $326.1M | (8.87%) |
| Sep 2025 | $357.9M | 136.00% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| IQV IQVIA Holdings Inc. compare | $2.3B |
| DGX Quest Diagnostics Incorporated compare | $1.3B |
| A Agilent Technologies, Inc. compare | $1.3B |
| IDXX IDEXX Laboratories, Inc. | $1.2B |
| ILMN Illumina, Inc. compare | $931.0M |
| MTD Mettler-Toledo International, Inc. compare | $864.0M |
| WAT Waters Corporation compare | $366.6M |
| NTRA Natera, Inc. compare | $84.2M |
| GH Guardant Health, Inc. compare | −$240.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on IDXX
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement